Switch theme
Sign up to access all valuation multiples
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
2015
145
LTM Revenue $87.9M
LTM EBITDA -$86.6M
$93.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gossamer Bio has a last 12-month revenue of $87.9M and a last 12-month EBITDA of -$86.6M.
In the most recent fiscal year, Gossamer Bio achieved revenue of $115M and an EBITDA of -$40.0M.
Gossamer Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gossamer Bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $115M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$162M | -$40.0M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -35% | XXX | XXX | XXX |
| Net Profit | -$229M | -$180M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -157% | XXX | XXX | XXX |
| Net Debt | $107M | $177M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Gossamer Bio's stock price is $1.
Gossamer Bio has current market cap of $185M, and EV of $93.1M.
See Gossamer Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $93.1M | $185M | XXX | XXX | XXX | XXX | $-0.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Gossamer Bio has market cap of $185M and EV of $93.1M.
Gossamer Bio's trades at 1.1x LTM EV/Revenue multiple, and -1.1x LTM EBITDA.
Analysts estimate Gossamer Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Gossamer Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $93.1M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | XXX | XXX |
| P/E | -3.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -26.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGossamer Bio's NTM/LTM revenue growth is -63%
Gossamer Bio's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Gossamer Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Gossamer Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Gossamer Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -35% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -75% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -98% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 32% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 121% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 152% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gossamer Bio acquired XXX companies to date.
Last acquisition by Gossamer Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Gossamer Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Gossamer Bio founded? | Gossamer Bio was founded in 2015. |
| Where is Gossamer Bio headquartered? | Gossamer Bio is headquartered in United States of America. |
| How many employees does Gossamer Bio have? | As of today, Gossamer Bio has 145 employees. |
| Who is the CEO of Gossamer Bio? | Gossamer Bio's CEO is Mr. Faheem Hasnain. |
| Is Gossamer Bio publicy listed? | Yes, Gossamer Bio is a public company listed on NAS. |
| What is the stock symbol of Gossamer Bio? | Gossamer Bio trades under GOSS ticker. |
| When did Gossamer Bio go public? | Gossamer Bio went public in 2019. |
| Who are competitors of Gossamer Bio? | Similar companies to Gossamer Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Gossamer Bio? | Gossamer Bio's current market cap is $185M |
| What is the current revenue of Gossamer Bio? | Gossamer Bio's last 12-month revenue is $87.9M. |
| What is the current EBITDA of Gossamer Bio? | Gossamer Bio's last 12-month EBITDA is -$86.6M. |
| What is the current EV/Revenue multiple of Gossamer Bio? | Current revenue multiple of Gossamer Bio is 1.1x. |
| What is the current EV/EBITDA multiple of Gossamer Bio? | Current EBITDA multiple of Gossamer Bio is -1.1x. |
| Is Gossamer Bio profitable? | Yes, Gossamer Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
